https://investors.seastarmedical.com/news/news-details/2022/SeaStar-Medicals-Lead-Product-Candidate-the-Selective-Cytopheretic-Device-SCD-Included-in-Consensus-Statement-for-Pediatric-Acute-Kidney-Injury-in-First-Pediatric-Acute-Disease-Quality-Initiative-ADQI-Meeting/default.aspx
Bernadette Ballard-Reid